Comparative Pharmacology
Head-to-head clinical analysis: ATACAND versus EDARBYCLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND versus EDARBYCLOR.
ATACAND vs EDARBYCLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination